LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

Search

AstraZeneca PLC

Uždarymo kaina

SektoriusSveikatos priežiūra

203.33 -1.12

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

202.33

Max

205.75

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-177M

2.4B

Pardavimai

312M

16B

P/E

Sektoriaus vid.

62.595

108.767

Pelnas, tenkantis vienai akcijai

1.19

Dividendų pajamingumas

1.67

Pelno marža

15.199

Darbuotojai

94,300

EBITDA

-530M

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+1.96% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.67%

2.21%

Kitas uždarbis

2026-04-29

Kitas dividendų mokėjimo data

2026-03-23

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

381B

584B

Ankstesnė atidarymo kaina

204.45

Ankstesnė uždarymo kaina

203.33

Naujienos nuotaikos

By Acuity

37%

63%

118 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

AstraZeneca PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-10 11:41; UTC

Uždarbis

AstraZeneca Reiterates $80 Billion Revenue Goal for 2030 -- Update

2026-02-10 07:39; UTC

Uždarbis

AstraZeneca Forecasts Continued Growth on Pipeline Strength

2026-02-10 14:41; UTC

Uždarbis
Karštos akcijos

BP, Ferrari, TSMC: Global Earnings in Focus -- WSJ

2026-02-10 13:18; UTC

Uždarbis
Karštos akcijos

Ferrari, BP, TSMC: Global Earnings in Focus -- WSJ

2026-02-10 12:01; UTC

Uždarbis

AstraZeneca 4Q Adj EPS $2.12 >AZN

2026-02-10 12:01; UTC

Uždarbis

AstraZeneca 4Q Rev $15.5B >AZN

2026-02-10 12:01; UTC

Uždarbis

AstraZeneca 4Q EPS $1.50 >AZN

2026-02-10 10:27; UTC

Uždarbis
Karštos akcijos

BP, Kering, Barclays: Earnings Around the World in Focus -- WSJ

2026-02-10 07:45; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca's Revenue Guidance Beats Expectations -- Market Talk

2026-02-10 07:08; UTC

Uždarbis

AstraZeneca: 2026 Core EPS Expected to Increase by Low Double-Digit Percentage

2026-02-10 07:07; UTC

Uždarbis

AstraZeneca: 2026 Total Revenue Expected to Increase by Mid-To-High Single-Digit Percentage

2026-02-10 07:05; UTC

Uždarbis

Analysts Saw AstraZeneca 4Q Adj EPS at $2.11

2026-02-10 07:04; UTC

Uždarbis

Analysts Saw AstraZeneca 4Q Revenue at $15.505B

2026-02-10 07:02; UTC

Uždarbis

AstraZeneca 4Q Adj EPS $2.12

2026-02-10 07:02; UTC

Uždarbis

AstraZeneca 4Q Rev $15.5B

2026-02-10 07:00; UTC

Uždarbis

AstraZeneca Issues 2026 View

2026-02-10 07:00; UTC

Uždarbis

AstraZeneca PLC 4Q Adj EPS $2.12

2026-02-10 07:00; UTC

Uždarbis

AstraZeneca PLC 4Q Pretax Pft $2.63B

2026-02-10 07:00; UTC

Uždarbis

AstraZeneca PLC 4Q Rev $15.5B

2026-02-10 07:00; UTC

Uždarbis

AstraZeneca PLC 4Q Oper Pft $2.98B

2026-02-10 07:00; UTC

Uždarbis

AstraZeneca PLC 4Q Net Pft $2.33B

2026-02-10 07:00; UTC

Uždarbis

AstraZeneca PLC 4Q EPS $1.49

2026-02-09 08:56; UTC

Uždarbis

AstraZeneca's Weight-Loss Drug Strategy in Focus -- Earnings Preview

2026-01-16 17:03; UTC

Rinkos pokalbiai

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

2026-01-12 10:19; UTC

Karštos akcijos

Stocks to Watch Monday: Capital One, Amex, Citi, Walmart -- WSJ

2025-12-30 08:45; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

A GSK, AstraZeneca Merger Could Be a Possibility -- Market Talk

2025-11-11 13:38; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca Shares Hit Record High After Earnings Beat, U.S. Price Deal -- Market Talk

2025-11-06 12:07; UTC

Rinkos pokalbiai

AstraZeneca Should Continue to Outpace Peers, Stick to Margin Goal -- Market Talk

2025-11-06 12:02; UTC

Uždarbis

AstraZeneca Sees FY25 Core EPS Increasing by Low Double-Digit Percentage >AZN.LN

2025-11-06 12:02; UTC

Uždarbis

AstraZeneca Sees FY25 Total Rev Increasing by High Single-Digit Percentage >AZN.LN

Akcijų palyginimas

Kainos pokytis

AstraZeneca PLC Prognozė

Kainos tikslas

By TipRanks

1.96% į viršų

12 mėnesių prognozė

Vidutinis 209.826 USD  1.96%

Aukščiausias 249.712 USD

Žemiausias 153.356 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AstraZeneca PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

13

Pirkti

2

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 69.55Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

118 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
help-icon Live chat